EU Diabetes Drugs Market, by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs) and by Drug type (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors)Growth, Trends and Forecast, 2019-2028
- Published Date: 2022-12-26
- Report ID: 138280
- Pages: 200
-
Format:
Report Overview
The EU Diabetes Drug market size stood at round USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 5.68% during the forecast period
Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. Diabetes is becoming an increasingly common health condition, which can disable patients and potentially lead to fatal health complications
Market Drivers
The growing number of individuals with diabetes and an increase in type 1 and type 2 diabetes awareness programs contributes to the market growth in this region. Certain genetic factors can also increase the risk of disease, including the stress level of the mother during pregnancy and the fathers eating habits long before the pregnancy. Therefore, the growing number of individuals with diabetes and the increase in type 1 and type 2 diabetes awareness programs contribute to the market growth in this region
1. EU Diabetes Drugs Market Overview
A. Market Size
2. EU Diabetes Drugs Growth Drivers
I. The growing number of individuals with diabetes and an increase in type 1 and type 2 diabetes awareness programs
II. The growing number of individuals with diabetes
3. EU Diabetes Drugs Market Segmentation.
A. By Categories
I. Insulin
II. Oral Anti-Diabetic Drugs
III. Non-Insulin Injectable Drugs, and Combination Drugs
B. By Drug Type
I. Basal or Long-acting
II. Bolus or Fast-acting
III. Traditional Human Insulin Drugs
IV. Insulin Biosimilars
V. GLP-1 Receptor Agonists
VI. Alpha-Glucosidase Inhibitors
VII. DPP-4 Inhibitors
VIII. SGLT-2 Inhibitors
4. EU Diabetes Drugs Market Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles
A. Eli-Lilly Company overview, Product & Services, Strategies & Financials
B. Astra Zeneca Company overview, Product & Services, Strategies & Financials
C. Novo Nordisk Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Market Opportunities and Future Trends
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
